<DOC>
	<DOCNO>NCT01367444</DOCNO>
	<brief_summary>Primary Objective : To assess safety tolerability ascend dos SAR422459 patient Stargardt 's Macular Degeneration . Secondary Objective : To evaluate possible biological activity SAR422459 .</brief_summary>
	<brief_title>Phase I/IIa Study SAR422459 Patients With Stargardt 's Macular Degeneration</brief_title>
	<detailed_description>The total duration per patient 52 week , include 4 week screen period 48 week study period . At end study , patient invite enter open-label safety study long-term follow-up visit include ophthalmological examination record adverse event 15 year .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<criteria>Signed date write informed consent obtain patient and/or patient 's legally acceptable representative . Diagnosis Stargardt 's Macular Degeneration , least one pathogenic mutant ABCA4 allele chromosome . Women childbearing potential must negative pregnancy test Day 1 , agree use effective form contraception least three month , surgically sterile postmenopausal , last menstrual period two year prior enrollment . Males must agree partner use two form contraception least three month follow SAR422459 administration . Patients must agree donate blood , tissue cell least three month follow SAR422459 administration . Patients enrol France must affiliate benefit social security regimen . Specific Inclusion Criteria Patient Group A : Patients ( 18 year old ) advance Stargardt 's Macular Degeneration . Visual acuity ≤20/200 bad eye . Severe conerod dysfunction detectable severely abnormal fullfield electroretinogram response . Specific Inclusion Criteria Patient Group B : Patients ( 18 year old ) Stargardt 's Macular Degeneration . Visual Acuity ≤20/200 bad eye . Abnormal fullfield electroretinogram response . Specific Inclusion Criteria Patient Group C : Patients ( 18 year old ) Stargardt 's Macular Degeneration . Visual acuity ≤20/100 bad eye . Abnormal fullfield electroretinogram response . Specific Inclusion Criteria Patient Group D : Symptomatic patient ( 6 year 26 year old ) early childhoodonset SMD ( age disease onset &lt; 18 year ) least one pathogenic mutant ABCA4 allele chromosome confirm direct sequencing cosegregation analysis within patient 's family . Visual acuity ≥20/200 eye time screen visit . Patients anticipated experience rapid deterioration visual function and/or retinal structure determine least one follow parameter occur within span year : Loss ≥1 line Snellen visual acuity ( equivalent 5 ETDRS letter ) . Reduction macular mean sensitivity ≥1.2 dB assess microperimetry . Reduction macular mean sensitivity ≥5 dB reduction hill vision &gt; 14 dBsr assess static perimetry . Enlargement area macular RPE atrophy fundus autofluorescence rate ≥0.5 mm^2 . Enlargement area central macular retinal thinning/photoreceptor loss ocular coherence tomography rate ≥0.5 mm^2 . All eligible patient must demonstrate ability understand , willingness cooperate ability reliably perform require study procedure judge confirm study investigator . Preexisting eye condition would preclude plan surgery interfere interpretation study endpoint . Cataract surgery intraocular lens implantation within 6 month enrolment . Aphakia prior vitrectomy study eye . Concomitant systemic disease include disease , treatment disease , alter ocular function . Any intraocular surgery laser either eye plan within 6 month Day 0 . Any contraindication pupil dilation either eye . Any known allergy component delivery vehicle diagnostic agent use study , medication plan use perioperative period particularly topical , injected systemic corticosteroid . Any injectable intravitreal treatment treat eye intravitreal device treat eye within 6 month prior screen . Any periocular injection corticosteroid treat eye within 4 month prior screen . Laboratory test abnormality abnormalities electrocardiogram , chest Xrays opinion Principal Investigator would make patient unsuitable participation study . Significant intercurrent illness infection 28 day prior enrolment . Premenopausal nonsurgically sterile woman unwilling use effective form contraception contraceptive pill intrauterine device . Alcohol substance abuse . Contraindications use anesthesia ( local general , appropriate ) . Concurrent antiretroviral therapy would inactivate investigational agent . History investigational agent within 28 day prior SAR422459 administration . Participation prior ocular gene transfer therapy study . Enrolment clinical treatment study throughout duration SAR422459 study . Current anticipate treatment anticoagulant therapy use anticoagulation therapy within four week prior surgery . A past medical history human immunodeficiency virus ( HIV ) hepatitis A , B , C infection . Women pregnant breastfeeding . History sign consistent unilateral amblyopia ( strabismic , anisometropic , stimulus deprivation ) .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Stargardt Disease</keyword>
</DOC>